Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 12:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 152 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Proton Pump Inhibitors Clear all
Completed Phase 2 Interventional Results available

Effect of Proton Pump Inhibitors on CF Pulmonary Exacerbations

NCT01983774
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Esomeprazole, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced Sep 9, 2026, 12:37 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Gastric Acid on Colonic Microbiome

NCT01901276
View directory record Official record
Conditions
Clostridium Difficile
Interventions
Omeprazole 40 mg bid
Drug
Lead sponsor
Daniel Freedberg, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Sep 9, 2026, 12:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Gastric pH and Anthocyanin Absorption

NCT01122160
View directory record Official record
Conditions
Anthocyanin Metabolism
Interventions
omeprazole, placebo
Drug
Lead sponsor
USDA Beltsville Human Nutrition Research Center
Federal
Eligibility
22 Years to 59 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Beltsville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 22, 2013 · Synced Sep 9, 2026, 12:37 AM EDT
Completed Phase 1 Interventional

A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast Cancer

NCT00849329
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
lapatinib, lapatinib plus esomeprazole
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Sep 9, 2026, 12:37 AM EDT
Terminated Phase 1 Interventional

A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib

NCT04959266
View directory record Official record
Conditions
Advanced Solid Tumours
Interventions
Adavosertib, Itraconazole, Rifampicin, Omeprazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Portland, Oregon • Austin, Texas • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2022 · Synced Sep 9, 2026, 12:37 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of an Oropharyngeal Aerosolized pH Probe for Diagnosing Laryngopharyngeal Reflux (LPR)

NCT00321503
View directory record Official record
Conditions
Laryngopharyngeal Reflux
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 8, 2013 · Synced Sep 9, 2026, 12:37 AM EDT
Completed Phase 2 Interventional Results available

Validation of Patient-reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) Symptoms

NCT00703534
View directory record Official record
Conditions
GERD, Acid Reflux Disease, Heartburn, Regurgitation
Interventions
AZD3355, Placebo, Gelusil®
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
84
States / cities
Athens, Alabama • Tucson, Arizona • Little Rock, Arkansas + 81 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2011 · Synced Sep 9, 2026, 12:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of Increased Gastric pH on the Oral Bioavailability of the Orexin-2 Receptor Antagonist JNJ-42847922 in Healthy Participants

NCT02475161
View directory record Official record
Conditions
Healthy
Interventions
JNJ-42847922, Rabeprazole
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 9, 2026, 12:37 AM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

EffCaMgCit to Prevent Mineral Metabolism and Renal Complications of Chronic PPI Therapy

NCT05998863
View directory record Official record
Conditions
Osteoporosis, Hypomagnesemia
Interventions
EffCaMgCit, Placebo
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years to 99 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 9, 2026, 12:37 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Obesity on Proton Pump Inhibitors

NCT04248335
View directory record Official record
Conditions
Pediatric Obesity, NAFLD, GERD
Interventions
Lansoprazole, Pantoprazole, Midazolam
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
6 Years to 21 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 9, 2026, 12:37 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

The Influence of Proton Pump Inhibitors (PPI's) on Blood Levels of 25-Hydroxyvitamin D.

NCT01302704
View directory record Official record
Conditions
Vitamin D
Interventions
Not listed
Lead sponsor
Mike O'Callaghan Military Hospital
Federal
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Nellis Air Force Base, Nevada
Source: ClinicalTrials.gov public record
Updated Nov 24, 2013 · Synced Sep 9, 2026, 12:37 AM EDT
Withdrawn No phase listed Observational

Transoral Incisionless Fundoplication (TIF) for Laryngopharyngeal Reflux (LPR) Patients

NCT05579587
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD), Laryngopharyngeal Reflux (LPR), Reflux Disease, Gastro-Esophageal, Motility Disorder
Interventions
Transoral Incisionless Fundoplication
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 4, 2024 · Synced Sep 9, 2026, 12:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Acalabrutinib Suspension to Evaluate Relative Bioavailability and Proton-pump Inhibitor Effect in Healthy Volunteers

NCT04435483
View directory record Official record
Conditions
Pharmacokinetics, Bioavailability
Interventions
Acalabrutinib Treatment A, Acalabrutinib Treatment B, Acalabrutinib Treatment C
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Sep 9, 2026, 12:37 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Determining Risk Factors for Successful PPI Weaning

NCT03226054
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Lifestyle Modifications
Behavioral
Lead sponsor
Mount Carmel Health System
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Westerville, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 3, 2018 · Synced Sep 9, 2026, 12:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Relative Bioavailability Study Evaluating Two New Encorafenib Formulations

NCT05446142
View directory record Official record
Conditions
Healthy
Interventions
Encorafenib capsule formulation (CAP), Encorafenib first formulation, Encorafenib second formulation, Rabeprazole tablet
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Sep 9, 2026, 12:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of H2 Antagonist and a Proton Pump Inhibitor of Selpercatinib in Healthy Participants

NCT05338502
View directory record Official record
Conditions
Healthy
Interventions
Selpercatinib, Ranitidine, Omeprazole
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Sep 9, 2026, 12:37 AM EDT
Terminated Phase 2 Interventional Results available

Role of Proton Pump Inhibitors on the Postoperative Course Following Pancreaticoduodenectomy

NCT05251233
View directory record Official record
Conditions
Pancreatic Cancer, Pancreas Cancer, Ampullary Cancer, Pancreas Neuroendocrine Tumor, Pancreatitis, Distal Extrahepatic Cholangiocarcinoma, Duodenal Cancer
Interventions
Placebo, Pantoprazole
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 5, 2025 · Synced Sep 9, 2026, 12:37 AM EDT
Terminated No phase listed Observational

Proton Pump Inhibitor Therapy and Bone Density in Premature Infants

NCT00888017
View directory record Official record
Conditions
Osteopenia, Prematurity
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 22, 2013 · Synced Sep 9, 2026, 12:37 AM EDT
Terminated Not applicable Interventional Results available

Optimal Dose of Proton Pump Inhibitors Following an Upper Gastrointestinal Bleed

NCT02235311
View directory record Official record
Conditions
Upper Gastrointestinal Bleed
Interventions
Pantoprazole
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 30, 2017 · Synced Sep 9, 2026, 12:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Surufatinib DDI With a PPI and a CYP3A Inducer

NCT04510649
View directory record Official record
Conditions
Healthy
Interventions
Part A, Part B
Drug
Lead sponsor
Hutchison Medipharma Limited
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2021 · Synced Sep 9, 2026, 12:37 AM EDT
Completed Phase 3 Interventional

Management of Myocardial Injury After Noncardiac Surgery Trial

NCT01661101
View directory record Official record
Conditions
Myocardial Injury After Noncardiac Surgery (MINS)
Interventions
Dabigatran, Placebo (for Dabigatran), Omeprazole, Placebo (for Omeprazole)
Drug
Lead sponsor
Population Health Research Institute
Other
Eligibility
45 Years and older
Enrollment
1,754 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
7
States / cities
Kansas City, Kansas • Buffalo, New York • Rochester, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2018 · Synced Sep 9, 2026, 12:37 AM EDT
Completed Phase 2 Interventional Results available

Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)

NCT01472939
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
SSP-002358 (0.1 mg) + PPI, SSP-002358 (0.5 mg) + PPI, SSP-002358 (2.0 mg) + PPI, Placebo + PPI
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 70 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
62
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 58 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Sep 9, 2026, 12:37 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effect of Proton Pump Inhibitors on Gut Microbiota and Systemic Inflammation in Older Adults

NCT02844621
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Omeprazole
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
60 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Sep 9, 2026, 12:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Pharmacokinetics (PK) of Brensocatib Alone and With Multiple Doses of Rifampin or Esomeprozole in Healthy Participants

NCT05826574
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Brensocatib, Rifampin, Esomeprazole
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Sep 9, 2026, 12:37 AM EDT